- Home
- OST vs TOVX Comparison
OST vs TOVX Comparison
Compare OST & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OST
- TOVX
- Stock Information
- Founded
- OST 2010
- TOVX 2001
- Country
- OST China
- TOVX United States
- Employees
- OST 226
- TOVX N/A
- Industry
- OST Industrial Machinery/Components
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- OST Technology
- TOVX Health Care
- Exchange
- OST Nasdaq
- TOVX Nasdaq
- Market Cap
- OST 3.6M
- TOVX 3.1M
- IPO Year
- OST 2022
- TOVX 2006
- Fundamental
- Price
- OST $0.24
- TOVX $1.37
- Analyst Decision
- OST
- TOVX Strong Buy
- Analyst Count
- OST 0
- TOVX 1
- Target Price
- OST N/A
- TOVX $6.00
- AVG Volume (30 Days)
- OST 497.7K
- TOVX 4.8M
- Earning Date
- OST 08-26-2024
- TOVX 11-12-2024
- Dividend Yield
- OST N/A
- TOVX N/A
- EPS Growth
- OST N/A
- TOVX N/A
- EPS
- OST N/A
- TOVX N/A
- Revenue
- OST $38,203,634.00
- TOVX N/A
- Revenue This Year
- OST N/A
- TOVX N/A
- Revenue Next Year
- OST N/A
- TOVX N/A
- P/E Ratio
- OST N/A
- TOVX N/A
- Revenue Growth
- OST N/A
- TOVX N/A
- 52 Week Low
- OST $0.22
- TOVX $1.24
- 52 Week High
- OST $1.07
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- OST 38.73
- TOVX 37.71
- Support Level
- OST $0.25
- TOVX $1.31
- Resistance Level
- OST $0.28
- TOVX $2.22
- Average True Range (ATR)
- OST 0.06
- TOVX 0.24
- MACD
- OST -0.01
- TOVX -0.00
- Stochastic Oscillator
- OST 5.95
- TOVX 4.51
About OST Ostin Technology Group Co. Ltd.
Ostin Technology Group Co Ltd is a supplier of display modules and polarizers in China. It designs, develops, and manufactures TFT-LCD modules in a wide range of sizes and customized sizes according to the specifications of its customers. Its display modules are mainly used in consumer electronics, commercial LCD displays, and automotive displays. The company also manufactures polarizers used in the TFT-LCD display modules and is in the process of developing polarizers for the OLED display panel. Geographically, the company generates revenue from Hong Kong, Taiwan, and Mainland China which is its key revenue generating market.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.